News and Information
Centerpoint Spring 2008 (PDF)
Dr. Madhav Dhodapkar Named Director of Hematologic Malignancies
Yale Cancer Center is pleased to welcome Madhav Dhodapkar, MD to the new position of Director of Hematologic Malignancies. The Arthur H. and Isabel Bunker Professor of Medicine at Yale School of Medicine and Chief of Hematology at Yale-New Haven Hospital, Dr. Dhodapkar’s clinical and research interests focus on the treatment of myeloma with a concentration on tumor-immune responses and development of novel biological therapies.
“Dr. Dhodapkar’s experience and expertise in the treatment of hematologic malignancies, especially in myeloma, is a true asset to Yale Cancer Center. With his leadership, mentorship skills, research accomplishments and innovative clinical approaches, we are looking forward to achieving new advances in the treatment of these diseases,” said Richard L. Edelson, MD, Director of Yale Cancer Center.
Dr. Dhodapkar earned his medical degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his Internal Medicine residency training at the St. Louis University Hospitals and continued on to the Mayo Clinic where he completed his fellowship in medical oncology and hematology. Dr. Dhodapkar focused his clinical activities on myeloma and related plasma cell diseases, initially at the Myeloma Institute in Little Rock, and then at Memorial Sloan Kettering Cancer Center. Prior to coming to Yale, Dr. Dhodapkar served as the Leon Hess Associate Professor and Head of the Lab of Tumor Immunology and Immunotherapy at The Rockefeller University.
